查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941816

疫苗市場規模、佔有率和趨勢分析報告：按適應症、類型、給藥途徑、年齡層、分銷管道、地區和細分市場預測（2026-2033 年）

Vaccine Market Size, Share & Trends Analysis Report By Indication, By Type, By Route Of Administration, By Age Group, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

疫苗市場概況

2025年全球疫苗市場規模估計為727.5億美元，預計2033年將達到1,157.7億美元。

預計從 2026 年到 2033 年，市場將以 5.78% 的複合年成長率成長。這一成長是由研發投入的增加以及贊助商和研究人員對降低研發成本日益成長的興趣所推動的。

此外，包括製藥和生技公司在內的終端用戶擴大採用外包實驗室服務以降低研發活動的總體成本，這也推動了預測期內的市場成長。全球疫苗產業被視為醫療保健系統的重要組成部分，其主要驅動力來自地方公共衛生免疫規劃、感染疾病防範和常規疾病預防措施。疫苗已被納入國家醫療保健預算和長期公共衛生計劃，因為它們有助於減輕疾病負擔和降低後續治療成本。根據世界衛生組織（世衛組織）估計，透過預防麻疹、白喉、破傷風、百日咳和流感等疫苗可預防疾病，免疫接種每年可在全球預防約200萬至300萬人死亡。 2024年4月，世衛組織在醫學期刊《採血針》上發表了一項綜合分析報告，指出全球免疫規劃在過去50年中已預防了約1.54億人死亡。這進一步證實了疫苗接種是公共衛生領域的核心投資。 2025年4月，世界衛生組織設立“世界免疫週”，專注於消除免疫接種差距、加強免疫接種服務體係以及提高終身疫苗接種率。這體現了全球政策持續將免疫接種作為核心公共衛生措施的優先事項。

市場成長的促進因素包括感染疾病的持續蔓延、成人和老年人免疫接種計劃的擴大，以及疫情相關中斷後常規免疫接種覆蓋率的恢復。根據世界衛生組織（世衛組織）發布的《2024年全球結核病報告》，預計2023年全球將有1080萬人患有結核病，其中東南亞和非洲等地區的結核病負擔最為沉重，這表明高負擔市場對預防和應對策略的需求持續存在。世衛組織於2024年4月發布的《全球肝炎報告》估計，全球約有2.54億人患有慢性B型肝炎，5,000萬人患有慢性C型肝炎，每年新增病毒性肝炎感染病例超過100萬例。這顯示肝炎仍然是全球持續存在的公共衛生負擔。 2025年5月，美國食品藥物管理局（FDA）核准了Moderna公司研發的下一代新冠疫苗mNEXSPIKE，用於65歲及以上的老年人和12至64歲患有基礎疾病的人。這顯示監管機構持續支持在高風險族群中推廣疫苗接種。

市場格局日益受到技術平台、產品系列和生產策略轉變的影響，反映出疫苗正朝著更廣泛的疾病覆蓋範圍和長期供應韌性的方向發展。基於平台的開發方法，特別是mRNA技術，能夠加快設計週期，提高抗原選擇的柔軟性，並促進聯合疫苗的研發，從而支持產品組合擴展到單一疾病產品之外。這些進步促使人們更加關注呼吸系統疾病的適應症和多病原體預防策略，尤其是在成人和老年人群中。 2022年9月，輝瑞和BioNTech啟動了基於mRNA的流感疫苗的III期臨床試驗，顯示mRNA平台的應用範圍已擴展到COVID-19以外的領域。 2025年5月，世界衛生組織（WHO）報告稱，其mRNA技術轉移計畫已擴展至15個全球合作夥伴，支持疫苗生產的分散化和區域生產能力的建設。同時，成人免疫框架的擴展和更廣泛的監管建議正在擴大疫苗的目標市場，涵蓋所有年齡層。這表明，市場演變並非由短期需求波動所驅動，而是由公共部門優先事項、平台多元化和人口結構變化所驅動。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：疫苗市場的變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章：疫苗市場：依適應症分類的業務分析

  • 按適應症分類的市場佔有率（2025 年和 2033 年）
  • 按適應症分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 病毒疫苗
  • 細菌疫苗
  • 癌症疫苗
  • 過敏疫苗
  • 其他

第5章：疫苗市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2025 年和 2033 年）
  • 按類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 次單位疫苗
  • 失活
  • 減毒活病毒疫苗
  • mRNA疫苗
  • 病毒載體疫苗

第6章：疫苗市場：按給藥途徑分類的業務分析

  • 按給藥途徑分類的市場佔有率（2025 年和 2033 年）
  • 按給藥途徑分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 口服
  • 注射
  • 鼻內

第7章：疫苗市場：依年齡層別分類的業務分析

  • 按年齡層別分類的市場佔有率（2025 年和 2033 年）
  • 按年齡層別分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 兒童
  • 成人

第8章：疫苗市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2025 年和 2033 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院和零售藥局
  • 政府供應商
  • 其他

第9章：疫苗市場：區域預測與趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Serum Institute of India Pvt. Ltd.
    • Seqirus
    • Sanofi
    • Merck &Co., Inc.
    • Pfizer Inc.
    • Moderna Inc.
    • Sinovac
    • BioNTech SE
    • AstraZeneca
Product Code: 978-1-68038-990-6

Vaccine Market Summary

The global vaccine market size was estimated at USD 72.75 billion in 2025 and is projected to reach USD 115.77 billion by 2033, growing at a CAGR of 5.78% from 2026 to 2033. The market is driven by the increasing investment in R&D and the rising focus of sponsors & investigators on reducing research costs.

Moreover, the increasing adoption of outsourcing laboratory services by pharmaceutical & biotechnology companies and other end users to reduce the overall cost of research activities further supports the market growth over the forecast period. The global vaccine industry is positioned as a strategic component of preventive healthcare systems and is primarily driven by public immunization programs, outbreak preparedness, and routine disease prevention initiatives across regions. Vaccines are integrated into national healthcare budgets and long-term public health planning due to their role in reducing disease burden and downstream treatment costs. According to the World Health Organization, immunization prevents an estimated 2-3 million deaths every year worldwide by protecting against vaccine-preventable diseases such as measles, diphtheria, tetanus, pertussis, and influenza. In April 2024, the WHO published a comprehensive analysis in The Lancet reporting that global immunization programs have prevented approximately 154 million deaths over the past 50 years, reinforcing vaccination as a central public health investment. In April 2025, the World Health Organization marked World Immunization Week with a focus on closing immunization gaps, strengthening immunization delivery systems, and expanding vaccine coverage across the life course, reflecting continued global policy prioritization of immunization as a core public health intervention.

Market growth is supported by the continued prevalence of infectious diseases, expansion of adult and geriatric immunization programs, and recovery of routine vaccination coverage following pandemic-related disruptions. According to the World Health Organization Global Tuberculosis Report 2024, an estimated 10.8 million people developed tuberculosis globally in 2023, with the highest burden concentrated in regions such as Southeast Asia and Africa, sustaining demand for preventive and control strategies in high-burden markets. In April 2024, the World Health Organization Global Hepatitis Report estimated that approximately 254 million people were living with chronic hepatitis B and 50 million with chronic hepatitis C worldwide, with more than 1 million new viral hepatitis infections occurring each year, underscoring the continued public health burden of hepatitis globally. In May 2025, the U.S. Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for older adults aged 65 years and above and for individuals aged 12-64 years with underlying medical conditions, indicating continued regulatory support for vaccine adoption among high-risk populations.

The market is increasingly shaped by shifts in technology platforms, product portfolios, and manufacturing strategies, reflecting a transition toward broader disease coverage and long-term supply resilience. Platform-based development approaches, particularly mRNA technologies, have enabled faster design cycles, greater flexibility in antigen selection, and the development of combination vaccines, supporting portfolio expansion beyond single-disease products. These advancements are contributing to increased focus on respiratory indications and multi-pathogen prevention strategies, particularly within adult and elderly populations. In September 2022, Pfizer and BioNTech initiated Phase III clinical trials for an mRNA-based influenza vaccine, marking the extension of mRNA platforms beyond COVID-19 applications. In May 2025, the World Health Organization reported that its mRNA Technology Transfer Programme had expanded to 15 global partners, supporting the decentralization of vaccine manufacturing and the development of regional production capacity. In parallel, expanding adult immunization frameworks and broader regulatory recommendations are increasing the addressable market for vaccines across age groups, indicating that market evolution is being driven by public-sector priorities, platform diversification, and demographic shifts rather than short-term demand fluctuations.

Global Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine market report based on indication, type, route of administration, age group, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Viral Vaccines
    • Hepatitis
    • Pediatric (Children)
    • Adult
    • Influenza
    • Pediatric (Children)
    • Adult
    • HPV
    • Pediatric (Children)
    • Adult
    • MMR
    • Pediatric (Children)
    • Adult
    • Rotavirus
    • Pediatric (Children)
    • Adult
    • Herpes Zoster
    • Pediatric (Children)
    • Adult
    • Japanese Encephalitis
    • Pediatric (Children)
    • Adult
    • RSV
    • Pediatric (Children)
    • Adult
    • Others
    • Pediatric (Children)
    • Adult
  • Bacterial Vaccines
    • Meningococcal Diseases
    • Pediatric (Children)
    • Adult
    • Pneumococcal diseases
    • Pediatric (Children)
    • Adult
    • DPT
    • Pediatric (Children)
    • Adult
    • Others
    • Pediatric (Children)
    • Adult
  • Cancer Vaccines
    • Pediatric (Children)
    • Adult
  • Allergy Vaccines
    • Pediatric (Children)
    • Adult
  • Other
    • Pediatric (Children)
    • Adult
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Subunit Vaccines
    • Recombinant Vaccines
    • Conjugate Vaccines
    • Toxoid Vaccines
  • Inactivated
  • Live Attenuated
  • mRNA Vaccines
  • Viral Vector Vaccines
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Parenteral
  • Nasal
  • Age Group Outlook (Revenue, USD Million, 2021 - 2033)
  • Pediatric
  • Adult
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Market Segmentation & Scope
  • 1.2 Segment Definitions
    • 1.2.1 Indication
    • 1.2.2 Type
    • 1.2.3 Route of Administration
    • 1.2.4 Age Group
    • 1.2.5 Distribution Channel
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Research Methodology
  • 1.5 Information Procurement
    • 1.5.1 Purchased Database
    • 1.5.2 GVR's Internal Database
    • 1.5.3 Secondary Sources
    • 1.5.4 Primary Research
  • 1.6 Information Analysis
    • 1.6.1 Data Analysis Models
  • 1.7 Market Formulation & Data Visualization
  • 1.8 Model Details
    • 1.8.1 Commodity Flow Analysis
  • 1.9 List of Secondary Sources
  • 1.10 Objectives

Chapter 2. Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3. Vaccine Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Market Restraint Analysis
  • 3.3 Business Environment Analysis
    • 3.3.1 Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1 Supplier Power
      • 3.3.1.2 Buyer Power
      • 3.3.1.3 Substitution Threat
      • 3.3.1.4 Threat of New Entrants
      • 3.3.1.5 Competitive Rivalry
    • 3.3.2 PESTLE Analysis
    • 3.3.3 Pipeline Analysis
    • 3.3.4 Patent Expiry Analysis
    • 3.3.5 Pricing Analysis

Chapter 4. Vaccine Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2025 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Viral Vaccines
    • 4.4.1 Viral Vaccine Market, 2021 - 2033 (USD Million)
      • 4.4.1.1 Hepatitis Market, 2021 - 2033 (USD Million)
        • 4.4.1.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.1.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.2 Influenza Market, 2021 - 2033 (USD Million)
        • 4.4.1.2.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.2.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.3 HPV Market, 2021 - 2033 (USD Million)
        • 4.4.1.3.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.3.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.4 MMR Market, 2021 - 2033 (USD Million)
        • 4.4.1.4.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.4.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.5 Rotavirus Market, 2021 - 2033 (USD Million)
        • 4.4.1.5.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.5.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.6 Herpes Zoster Market, 2021 - 2033 (USD Million)
        • 4.4.1.6.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.6.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.7 Japanese Encephalitis Market, 2021 - 2033 (USD Million)
        • 4.4.1.7.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.7.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.8 RSV Market, 2021 - 2033 (USD Million)
        • 4.4.1.8.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.8.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.9 Others Market, 2021 - 2033 (USD Million)
        • 4.4.1.9.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.9.2 Adult Market, 2021 - 2033 (USD Million)
  • 4.5. Bacterial Vaccines
    • 4.5.1 Bacterial Vaccine Market, 2021 - 2033 (USD Million)
      • 4.5.1.1 Meningococcal Diseases Market, 2021 - 2033 (USD Million)
      • 4.5.1.2 Pneumococcal diseases Market, 2021 - 2033 (USD Million)
      • 4.5.1.3 DPT Market, 2021 - 2033 (USD Million)
      • 4.5.1.4 Others Market, 2021 - 2033 (USD Million)
  • 4.6. Cancer Vaccines
    • 4.6.1 Cancer Vaccine Market, 2021 - 2033 (USD Million)
      • 4.6.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.6.1.2 Adult Market, 2021 - 2033 (USD Million)
  • 4.7. Allergy Vaccines
    • 4.7.1 Allergy Vaccine Market, 2021 - 2033 (USD Million)
      • 4.7.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.7.1.2 Adult Market, 2021 - 2033 (USD Million)
  • 4.8. Other
    • 4.8.1 Other Market, 2021 - 2033 (USD Million)
      • 4.8.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.8.1.2 Adult Market, 2021 - 2033 (USD Million)

Chapter 5. Vaccine Market: Type Business Analysis

  • 5.1. Type Market Share, 2025 & 2033
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Subunit Vaccines
    • 5.4.1 Subunit Vaccine Market, 2021 - 2033 (USD Million)
      • 5.4.1.1 Recombinant Vaccine Market, 2021 - 2033 (USD Million)
      • 5.4.1.2 Conjugate Vaccine Market, 2021 - 2033 (USD Million)
      • 5.4.1.3 Toxoid Vaccine Market, 2021 - 2033 (USD Million)
  • 5.5. Inactivated
    • 5.5.1 Inactivated Market, 2021 - 2033 (USD Million)
  • 5.6. Live Attenuated
    • 5.6.1 Live Attenuated Market, 2021 - 2033 (USD Million)
  • 5.7. mRNA Vaccines
    • 5.7.1 mRNA Vaccine Market, 2021 - 2033 (USD Million)
  • 5.8. Viral Vector Vaccines
    • 5.8.1 Viral Vector Vaccine Market, 2021 - 2033 (USD Million)

Chapter 6. Vaccine Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1 Oral Market, 2021 - 2033 (USD Million)
  • 6.5. Parenteral
    • 6.5.1 Parenteral Market, 2021 - 2033 (USD Million)
  • 6.6. Nasal
    • 6.6.1 Nasal Market, 2021 - 2033 (USD Million)

Chapter 7. Vaccine Market: Age Group Business Analysis

  • 7.1. Age Group Market Share, 2025 & 2033
  • 7.2. Age Group Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
  • 7.4. Pediatric
    • 7.4.1 Pediatric Market, 2021 - 2033 (USD Million)
  • 7.5. Adult
    • 7.5.1 Adult Market, 2021 - 2033 (USD Million)

Chapter 8. Vaccine Market: Distribution Channel Business Analysis

  • 8.1. Distribution Channel Market Share, 2025 & 2033
  • 8.2. Distribution Channel Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 8.4. Hospital & Retail Pharmacies
  • 8.5. Government Suppliers
    • 8.5.1 Government Suppliers Market, 2021 - 2033 (USD Million)
  • 8.6. Others
    • 8.6.1 Others Market, 2021 - 2033 (USD Million)

Chapter 9. Vaccine Market: Regional Estimates & Trend Analysis

  • 9.1 Regional Market Share Analysis, 2025 & 2033
  • 9.2 Regional Market Dashboard
  • 9.3 Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 9.4 North America
    • 9.4.1 North America Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.4.2 U.S.
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Regulatory Framework
      • 9.4.2.3 Pricing Analysis
      • 9.4.2.4 U.S. Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3 Canada
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 Regulatory Framework
      • 9.4.3.3 Pricing Analysis
      • 9.4.3.4 Canada Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4 Mexico
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 Regulatory Framework
      • 9.4.4.3 Pricing Analysis
      • 9.4.4.4 Mexico Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5 Europe
    • 9.5.1 Europe Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.5.2 UK
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Regulatory Framework
      • 9.5.2.3 Pricing Analysis
      • 9.5.2.4 UK Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3 Germany
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Regulatory Framework
      • 9.5.3.3 Pricing Analysis
      • 9.5.3.4 Germany Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4 France
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Regulatory Framework
      • 9.5.4.3 Pricing Analysis
      • 9.5.4.4 France Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5 Italy
      • 9.5.5.1 Key Country Dynamics
      • 9.5.5.2 Regulatory Framework
      • 9.5.5.3 Pricing Analysis
      • 9.5.5.4 Italy Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6 Spain
      • 9.5.6.1 Key Country Dynamics
      • 9.5.6.2 Regulatory Framework
      • 9.5.6.3 Pricing Analysis
      • 9.5.6.4 Spain Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7 Denmark
      • 9.5.7.1 Key Country Dynamics
      • 9.5.7.2 Regulatory Framework
      • 9.5.7.3 Pricing Analysis
      • 9.5.7.4 Denmark Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.8 Norway
      • 9.5.8.1 Key Country Dynamics
      • 9.5.8.2 Regulatory Framework
      • 9.5.8.3 Pricing Analysis
      • 9.5.8.4 Norway Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.9 Sweden
      • 9.5.9.1 Key Country Dynamics
      • 9.5.9.2 Regulatory Framework
      • 9.5.9.3 Pricing Analysis
      • 9.5.9.4 Sweden Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6 Asia Pacific
    • 9.6.1 Asia Pacific Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.6.2 Japan
      • 9.6.2.1 Key Country Dynamics
      • 9.6.2.2 Regulatory Framework
      • 9.6.2.3 Pricing Analysis
      • 9.6.2.4 Japan Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3 China
      • 9.6.3.1 Key Country Dynamics
      • 9.6.3.2 Regulatory Framework
      • 9.6.3.3 Pricing Analysis
      • 9.6.3.4 China Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4 India
      • 9.6.4.1 Key Country Dynamics
      • 9.6.4.2 Regulatory Framework
      • 9.6.4.3 Pricing Analysis
      • 9.6.4.4 India Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5 South Korea
      • 9.6.5.1 Key Country Dynamics
      • 9.6.5.2 Regulatory Framework
      • 9.6.5.3 Pricing Analysis
      • 9.6.5.4 South Korea Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.6 Australia
      • 9.6.6.1 Key Country Dynamics
      • 9.6.6.2 Regulatory Framework
      • 9.6.6.3 Pricing Analysis
      • 9.6.6.4 Australia Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.7 Thailand
      • 9.6.7.1 Key Country Dynamics
      • 9.6.7.2 Regulatory Framework
      • 9.6.7.3 Pricing Analysis
      • 9.6.7.4 Thailand Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7 Latin America
    • 9.7.1 Latin America Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.7.2 Brazil
      • 9.7.2.1 Key Country Dynamics
      • 9.7.2.2 Regulatory Framework
      • 9.7.2.3 Pricing Analysis
      • 9.7.2.4 Brazil Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.3 Argentina
      • 9.7.3.1 Key Country Dynamics
      • 9.7.3.2 Regulatory Framework
      • 9.7.3.3 Pricing Analysis
      • 9.7.3.4 Argentina Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8 Middle East & Africa
    • 9.8.1 Middle East & Africa Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.8.2 South Africa
      • 9.8.2.1 Key Country Dynamics
      • 9.8.2.2 Regulatory Framework
      • 9.8.2.3 Pricing Analysis
      • 9.8.2.4 South Africa Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.3 Saudi Arabia
      • 9.8.3.1 Key Country Dynamics
      • 9.8.3.2 Regulatory Framework
      • 9.8.3.3 Pricing Analysis
      • 9.8.3.4 Saudi Arabia Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.4 UAE
      • 9.8.4.1 Key Country Dynamics
      • 9.8.4.2 Regulatory Framework
      • 9.8.4.3 Pricing Analysis
      • 9.8.4.4 UAE Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.5 Kuwait
      • 9.8.5.1 Key Country Dynamics
      • 9.8.5.2 Regulatory Framework
      • 9.8.5.3 Pricing Analysis
      • 9.8.5.4 Kuwait Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1 Serum Institute of India Pvt. Ltd.
      • 10.5.1.1 Overview
      • 10.5.1.2 Financial Performance
      • 10.5.1.3 Application Benchmarking
      • 10.5.1.4 Strategic Initiatives
    • 10.5.2 Seqirus
      • 10.5.2.1 Overview
      • 10.5.2.2 Financial Performance
      • 10.5.2.3 Application Benchmarking
      • 10.5.2.4 Strategic Initiatives
    • 10.5.3 Sanofi
      • 10.5.3.1 Overview
      • 10.5.3.2 Financial Performance
      • 10.5.3.3 Application Benchmarking
      • 10.5.3.4 Strategic Initiatives
    • 10.5.4 Merck & Co., Inc.
      • 10.5.4.1 Overview
      • 10.5.4.2 Financial Performance
      • 10.5.4.3 Application Benchmarking
      • 10.5.4.4 Strategic Initiatives
    • 10.5.5 Pfizer Inc.
      • 10.5.5.1 Overview
      • 10.5.5.2 Financial Performance
      • 10.5.5.3 Application Benchmarking
      • 10.5.5.4 Strategic Initiatives
    • 10.5.6 Moderna Inc.
      • 10.5.6.1 Overview
      • 10.5.6.2 Financial Performance
      • 10.5.6.3 Application Benchmarking
      • 10.5.6.4 Strategic Initiatives
    • 10.5.7 Sinovac
      • 10.5.7.1 Overview
      • 10.5.7.2 Financial Performance
      • 10.5.7.3 Application Benchmarking
      • 10.5.7.4 Strategic Initiatives
    • 10.5.8 BioNTech SE
      • 10.5.8.1 Overview
      • 10.5.8.2 Financial Performance
      • 10.5.8.3 Application Benchmarking
      • 10.5.8.4 Strategic Initiatives
    • 10.5.9 AstraZeneca
      • 10.5.9.1 Overview
      • 10.5.9.2 Financial Performance
      • 10.5.9.3 Application Benchmarking
      • 10.5.9.4 Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Vaccine Market, by Region, 2021 - 2033 (USD Million)
  • Table 4. Global Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 5. Global Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 6. Global Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 7. Global Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 8. Global Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 9. North America Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 10. North America Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 11. North America Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 12. North America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 13. North America Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 14. North America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 15. U.S. Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 16. U.S. Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 17. U.S. Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 18. U.S. Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 19. U.S. Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 20. Canada Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 21. Canada Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 22. Canada Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 23. Canada Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 24. Canada Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 25. Mexico Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 26. Mexico Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 27. Mexico Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 28. Mexico Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 29. Mexico Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 30. Europe Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 31. Europe Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 32. Europe Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 33. Europe Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 34. Europe Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 35. Europe Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 36. UK Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 37. UK Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 38. UK Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 39. UK Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 40. UK Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 41. Germany Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 42. Germany Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 43. Germany Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 44. Germany Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 45. Germany Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 46. France Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 47. France Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 48. France Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 49. France Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 50. France Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 51. Italy Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 52. Italy Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 53. Italy Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 54. Italy Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 55. Italy Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 56. Spain Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 57. Spain Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 58. Spain Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 59. Spain Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 60. Spain Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 61. Denmark Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 62. Denmark Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 63. Denmark Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 64. Denmark Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 65. Denmark Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 66. Norway Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 67. Norway Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 68. Norway Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 69. Norway Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 70. Norway Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 71. Sweden Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 72. Sweden Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 73. Sweden Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 74. Sweden Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 75. Sweden Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 76. Asia Pacific Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 77. Asia Pacific Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 78. Asia Pacific Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 79. Asia Pacific Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 80. Asia Pacific Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 81. Asia Pacific Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 82. Japan Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 83. Japan Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 84. Japan Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 85. Japan Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 86. Japan Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 87. China Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 88. China Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 89. China Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 90. China Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 91. China Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 92. India Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 93. India Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 94. India Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 95. India Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 96. India Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 97. South Korea Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 98. South Korea Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 99. South Korea Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 100. South Korea Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 101. South Korea Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 102. Australia Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 103. Australia Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 104. Australia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 105. Australia Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 106. Australia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 107. Thailand Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 108. Thailand Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 109. Thailand Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 110. Thailand Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 111. Thailand Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 112. Latin America Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 113. Latin America Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 114. Latin America Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 115. Latin America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 116. Latin America Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 117. Latin America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 118. Brazil Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 119. Brazil Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 120. Brazil Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 121. Brazil Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 122. Brazil Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 123. Argentina Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 124. Argentina Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 125. Argentina Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 126. Argentina Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 127. Argentina Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 128. Middle East & Africa Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 129. Middle East & Africa Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 130. Middle East & Africa Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 131. Middle East & Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 132. Middle East & Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 133. Middle East & Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 134. South Africa Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 135. South Africa Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 136. South Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 137. South Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 138. South Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 139. Saudi Arabia Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 140. Saudi Arabia Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 141. Saudi Arabia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 142. Saudi Arabia Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 143. Saudi Arabia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 144. UAE Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 145. UAE Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 146. UAE Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 147. UAE Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 148. UAE Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 149. Kuwait Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 150. Kuwait Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 151. Kuwait Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 152. Kuwait Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 153. Kuwait Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Vaccine Market outlook
  • Fig. 14 Vaccine Market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Vaccine Market driver impact
  • Fig. 20 Vaccine Market restraint impact
  • Fig. 21 Vaccine Market strategic initiatives analysis
  • Fig. 22 Vaccine Market Indication movement analysis
  • Fig. 23 Vaccine Market Indication outlook and key takeaways
  • Fig. 24 Viral Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 25 Hepatitis market estimates and forecast, 2021 - 2033
  • Fig. 26 Influenza market estimates and forecast, 2021 - 2033
  • Fig. 27 HPV market estimates and forecast, 2021 - 2033
  • Fig. 28 MMR market estimates and forecast, 2021 - 2033
  • Fig. 29 Rotavirus market estimates and forecast, 2021 - 2033
  • Fig. 30 Herpes Zoster market estimates and forecast, 2021 - 2033
  • Fig. 31 Japanese Encephalitis market estimates and forecast, 2021 - 2033
  • Fig. 32 RSV market estimates and forecast, 2021 - 2033
  • Fig. 33 Others market estimates and forecasts, 2021 - 2033
  • Fig. 34 Bacterial Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 35 Meningococcal Diseases market estimates and forecast, 2021 - 2033
  • Fig. 36 Pneumococcal diseases market estimates and forecast, 2021 - 2033
  • Fig. 37 DPT market estimates and forecast, 2021 - 2033
  • Fig. 38 Others market estimates and forecasts, 2021 - 2033
  • Fig. 39 Cancer Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 40 Pediatric (Children) market estimates and forecast, 2021 - 2033
  • Fig. 41 Adult market estimates and forecast, 2021 - 2033
  • Fig. 42 Allergy Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 43 Pediatric (Children) market estimates and forecast, 2021 - 2033
  • Fig. 44 Adult market estimates and forecast, 2021 - 2033
  • Fig. 45 Other market estimates and forecast, 2021 - 2033
  • Fig. 46 Pediatric (Children) market estimates and forecast, 2021 - 2033
  • Fig. 47 Adult market estimates and forecast, 2021 - 2033
  • Fig. 48 Vaccine Market Type movement analysis
  • Fig. 49 Vaccine Market Type outlook and key takeaways
  • Fig. 50 Subunit Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 51 Recombinant Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 52 Conjugate Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 53 Toxoid Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 54 Inactivated market estimates and forecasts, 2021 - 2033
  • Fig. 55 Live Attenuated market estimates and forecast, 2021 - 2033
  • Fig. 56 mRNA Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 57 Viral Vector Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 58 Vaccine Market Route of Administration movement analysis
  • Fig. 59 Vaccine Market Route of Administration outlook and key takeaways
  • Fig. 60 Oral market estimates and forecast, 2021 - 2033
  • Fig. 61 Parenteral market estimates and forecast, 2021 - 2033
  • Fig. 62 Nasal market estimates and forecast, 2021 - 2033
  • Fig. 63 Vaccine Market Age Group movement analysis
  • Fig. 64 Vaccine Market Age Group outlook and key takeaways
  • Fig. 65 Pediatric market estimates and forecast, 2021 - 2033
  • Fig. 66 Adult market estimates and forecast, 2021 - 2033
  • Fig. 67 Vaccine Market Distribution Channel movement analysis
  • Fig. 68 Vaccine Market Distribution Channel outlook and key takeaways
  • Fig. 69 Hospital & Retail Pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 70 Government Suppliers market estimates and forecast, 2021 - 2033
  • Fig. 71 Others market estimates and forecasts, 2021 - 2033
  • Fig. 72 Vaccine Market Regional movement analysis
  • Fig. 73 Vaccine Market Regional outlook and key takeaways
  • Fig. 74 Vaccine Market share and leading players
  • Fig. 75 North America Vaccine Market share and leading players
  • Fig. 76 Europe Vaccine Market share and leading players
  • Fig. 77 Asia Pacific Vaccine Market share and leading players
  • Fig. 78 Latin America Vaccine Market share and leading players
  • Fig. 79 Middle East & Africa Vaccine Market share and leading players
  • Fig. 80 North America Vaccine Market SWOT Analysis
  • Fig. 81 Europe Vaccine Market SWOT Analysis
  • Fig. 82 Asia Pacific Vaccine Market SWOT Analysis
  • Fig. 83 Latin America Vaccine Market SWOT Analysis
  • Fig. 84 Middle East & Africa Vaccine Market SWOT Analysis
  • Fig. 85 North America Vaccine Market Analysis, by country
  • Fig. 86 North America
  • Fig. 87 North America Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 88 US
  • Fig. 89 US Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 90 Canada
  • Fig. 91 Canada Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 92 Mexico
  • Fig. 93 Mexico Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 94 Europe
  • Fig. 95 Europe Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 96 UK
  • Fig. 97 UK Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 98 Germany
  • Fig. 99 Germany Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 100 France
  • Fig. 101 France Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 102 Italy
  • Fig. 103 Italy Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 104 Spain
  • Fig. 105 Spain Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 106 Denmark
  • Fig. 107 Denmark Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 108 Sweden
  • Fig. 109 Sweden Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 110 Norway
  • Fig. 111 Norway Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 112 Asia Pacific
  • Fig. 113 Asia Pacific Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 114 China
  • Fig. 115 China Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 116 Japan
  • Fig. 117 Japan Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 118 India
  • Fig. 119 India Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 120 Thailand
  • Fig. 121 Thailand Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 122 South Korea
  • Fig. 123 South Korea Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 124 Australia
  • Fig. 125 Australia Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 126 Latin America
  • Fig. 127 Latin America Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 128 Brazil
  • Fig. 129 Brazil Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 130 Argentina
  • Fig. 131 Argentina Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 132 Middle East & Africa
  • Fig. 133 Middle East & Africa Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 134 South Africa
  • Fig. 135 South Africa Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 136 Saudi Arabia
  • Fig. 137 Saudi Arabia Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 138 UAE
  • Fig. 139 UAE Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 140 Kuwait
  • Fig. 141 Kuwait Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 142 Market share of key market players - Vaccine Market